1
|
Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies. Biomolecules 2022; 12:biom12091261. [PMID: 36139103 PMCID: PMC9496523 DOI: 10.3390/biom12091261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2022] [Revised: 08/31/2022] [Accepted: 09/02/2022] [Indexed: 11/17/2022] Open
Abstract
CD38 was first discovered as a T-cell antigen and has since been found ubiquitously expressed in various hematopoietic cells, including plasma cells, NK cells, B cells, and granulocytes. More importantly, CD38 expression levels on malignant hematopoietic cells are significantly higher than counterpart healthy cells, thus presenting itself as a promising therapeutic target. In fact, for many aggressive hematological cancers, including CLL, DLBCL, T-ALL, and NKTL, CD38 expression is significantly associated with poorer prognosis and a hyperproliferative or metastatic phenotype. Studies have shown that, beyond being a biomarker, CD38 functionally mediates dysregulated survival, adhesion, and migration signaling pathways, as well as promotes an immunosuppressive microenvironment conducive for tumors to thrive. Thus, targeting CD38 is a rational approach to overcoming these malignancies. However, clinical trials have surprisingly shown that daratumumab monotherapy has not been very effective in these other blood malignancies. Furthermore, extensive use of daratumumab in MM is giving rise to a subset of patients now refractory to daratumumab treatment. Thus, it is important to consider factors modulating the determinants of response to CD38 targeting across different blood malignancies, encompassing both the transcriptional and post-transcriptional levels so that we can diversify the strategy to enhance daratumumab therapeutic efficacy, which can ultimately improve patient outcomes.
Collapse
|
2
|
Zawati I, Adouni O, Manai M, Nagara M, Tacam M, Reduzzi C, Gamoudi A, Manai M. FOXP3+/CD68+ ratio within the tumor microenvironment may serve as a potential prognostic factor in classical Hodgkin lymphoma. Hum Immunol 2022; 83:843-856. [PMID: 36068099 DOI: 10.1016/j.humimm.2022.08.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2022] [Revised: 08/21/2022] [Accepted: 08/23/2022] [Indexed: 11/19/2022]
Abstract
Classical Hodgkin lymphoma (CHL) is characterized by extensive inflammatory immune cells, which predict the disease prognosis. Therefore, this study aimed to explore the significance of different tumor-infiltrated immune cells and subpopulation ratios observed in the tumor microenvironment of CHL, particularly relating to the disease's prognosis-focusing on overall survival (OS) and event-free survival (EFS). Utilizing immunohistochemistry, the quantification and exploration of selected immune cells' subsets, including CD3+, CD4+, CD8+, FOXP3+, CD20+, and CD68+ were conducted on 102 histological samples with primary CHL. Eosinophils were pathologically assessed. Besides, we determined the ratios between different tumor-infiltrated immune cells for each patient. Kaplan-Meier method and Cox regression modeling were used for survival analysis. We demonstrated that among all ratios and immune cells individually, only a higher FOXP3+/CD68+ ratio (≥1.36 cutoff) displayed a tendency towards a favorable OS (p = 0.057, HR = 0.43 [0.18-1.02]) and EFS (p = 0.067, HR = 0.44 [0.18-1.06]) using Cox regression modeling. Moreover, the Kaplan-Meier method showed an association of a higher FOXP3+/CD68+ ratio with a longer 5-years OS (p = 0.037) and a tendency to a better EFS (p = 0.051); however, neither the combined FOXP3+ and CD68+ nor FOXP3+ or CD68+ separately was correlated to the CHL survival. Together, these results demonstrated that the FOXP3+/CD68+ ratio could predict the outcomes of CHL, providing more informative significance than FOXP3+ and CD68+ combined or FOXP3+ and CD68+ individually and might be a potential indicator of risk stratification, which has an important value for guiding the clinical treatment.
Collapse
Affiliation(s)
- Imen Zawati
- Department of Immuno-Histo-Cytology, Salah Azaiez Institute, 1006 Tunis, Tunisia; Department of Biology, Mycology, Pathologies, and Biomarkers Laboratory (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar, 2092 Ariana, Tunisia.
| | - Olfa Adouni
- Department of Immuno-Histo-Cytology, Salah Azaiez Institute, 1006 Tunis, Tunisia; Department of Biology, Mycology, Pathologies, and Biomarkers Laboratory (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar, 2092 Ariana, Tunisia
| | - Maroua Manai
- Department of Immuno-Histo-Cytology, Salah Azaiez Institute, 1006 Tunis, Tunisia; Laboratory of Human Genetics (LR99ES10), Faculty of Medicine of Tunis, University of Tunis El Manar, 2092 Tunis, Tunisia; Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, 1300 York Ave, 10021 NY, NY, USA
| | - Majdi Nagara
- Inserm, UMR-S 1251, MMG, Faculty of Medicine Timone, Aix Marseille University, Marseille, France
| | - Moisis Tacam
- Department of OB/Gyn, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA
| | - Carolina Reduzzi
- Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, 1300 York Ave, 10021 NY, NY, USA
| | - Amor Gamoudi
- Department of Immuno-Histo-Cytology, Salah Azaiez Institute, 1006 Tunis, Tunisia
| | - Mohamed Manai
- Department of Biology, Mycology, Pathologies, and Biomarkers Laboratory (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar, 2092 Ariana, Tunisia
| |
Collapse
|
3
|
Gao H, Cai F, Liu L, Shen H. Flow cytometry assessment of reactive T-cells distinguishes classic Hodgkin lymphoma from benign lymphadenopathy in children. J Clin Lab Anal 2022; 36:e24661. [PMID: 35989518 PMCID: PMC9550978 DOI: 10.1002/jcla.24661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Revised: 07/20/2022] [Accepted: 08/02/2022] [Indexed: 11/11/2022] Open
Abstract
Background Detection of classic Hodgkin lymphoma (cHL) neoplastic cells using flow cytometric immunophenotyping (FCI) remains limited. We hypothesized that characterization of the reactive infiltrates could assist in diagnosing cHL in children. Methods FCI using four‐color staining approaches was performed on 156 lymph node specimens with the following histopathologic diagnoses: cHL (25 cases), reactive lymphoid hyperplasia (RLH, 44 cases), and non‐Hodgkin lymphoma (87 cases). Results The overall concordance of FCI data with the histopathologic results of these cases was 81.4%. A reactive expansion of T‐cells with increased expression of CD45RO was present in the reactive infiltrate of cHL (CD45RO/CD3, 67.5%) and Epstein–Barr virus (EBV) infected RLH (62.7%) but not in EBV‐negative RLH (28.0%). The mean fluorescence intensity (MFI) of CD7 was higher for cHL and differed significantly from EBV‐positive RLH (138.5 vs. 63.8). A proposed diagnostic algorithm markedly elevated the overall concordance rate from 81.4% to 97.4%. Conclusions Immunophenotyping the reactive infiltrate of lymphoid tissue using flow cytometry is a reliable supplement to histopathology for the rapid diagnosis of pediatric cHL.
Collapse
Affiliation(s)
- Hui Gao
- Department of Clinical Laboratory, The Children's Hospital Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
| | - Fengqing Cai
- Department of Clinical Laboratory, The Children's Hospital Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
| | - Lei Liu
- Department of Pathology, The Children's Hospital Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
| | - Hongqiang Shen
- Department of Clinical Laboratory, The Children's Hospital Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
| |
Collapse
|
4
|
Calabretta E, Carlo-Stella C. The Many Facets of CD38 in Lymphoma: From Tumor-Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy. Cells 2020; 9:E802. [PMID: 32225002 PMCID: PMC7226059 DOI: 10.3390/cells9040802] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2020] [Revised: 03/19/2020] [Accepted: 03/25/2020] [Indexed: 12/13/2022] Open
Abstract
The CD38 antigen is expressed in several hematological malignancies, and the anti-CD38 monoclonal antibodies Daratumumab and Isatuximab have an established role in the therapy of multiple myeloma. However, data on the therapeutic utility of CD38 targeting in other lymphoid malignancies are limited. In chronic lymphocytic leukemia, the prognostic significance of CD38 expression is well accepted, and preclinical studies on the use of Daratumumab in monotherapy or combination therapy have demonstrated considerable efficacy. In other lymphoproliferative disorders, preclinical and clinical data have not been as compelling; however, CD38 overexpression likely contributes to resistance to checkpoint inhibitors, prompting numerous clinical trials in Hodgkin and non-Hodgkin lymphoma to investigate whether blocking CD38 enhances the efficacy of checkpoint inhibitors. Furthermore, due to its widespread expression in hematological tumors, CD38 represents an attractive target for cellular therapies such as CAR-T cells. The present review discusses current knowledge of CD38 expression and its implications in various lymphoid malignancies. Furthermore, it addresses current and future therapeutic perspectives, with a particular emphasis on the significance of CD38 interaction with immune cells of the tumor microenvironment. Lastly, results of ongoing studies using anti-CD38 antibodies will be reviewed.
Collapse
Affiliation(s)
- Eleonora Calabretta
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, 20089 Milano, Italy;
| | - Carmelo Carlo-Stella
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, 20089 Milano, Italy;
- Department of Biomedical Sciences, Humanitas University, Rozzano, 20089 Milano, Italy
| |
Collapse
|
5
|
Martin TG, Corzo K, Chiron M, van de Velde H, Abbadessa G, Campana F, Solanki M, Meng R, Lee H, Wiederschain D, Zhu C, Rak A, Anderson KC. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. Cells 2019; 8:E1522. [PMID: 31779273 PMCID: PMC6953105 DOI: 10.3390/cells8121522] [Citation(s) in RCA: 104] [Impact Index Per Article: 20.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2019] [Revised: 11/22/2019] [Accepted: 11/23/2019] [Indexed: 12/24/2022] Open
Abstract
CD38 is a transmembrane glycoprotein with ectoenzymatic activity involved in regulation of migration, signal transduction, and receptor-mediated adhesion. CD38 is highly expressed on various malignant cells, including multiple myeloma (MM), and at relatively low levels in other tissues, making it a suitable target for therapeutic antibodies. Several anti-CD38 therapies have been, or are being, developed for the treatment of MM, including daratumumab and isatuximab (SAR650984), respectively. Studies have shown that anti-CD38 therapies are effective in the treatment of relapsed/refractory MM and are well tolerated, with infusion reactions being the most common side effects. They can be used as monotherapy or in combination with immunomodulatory agents, such as pomalidomide, or proteasome inhibitors to potentiate their activity. Here we examine isatuximab and several anti-CD38 agents in development that were generated using new antibody engineering techniques and that may lead to more effective CD38 targeting. We also summarize trials assessing these antibodies in MM, other malignancies, and solid organ transplantation. Finally, we propose that further research on the mechanisms of resistance to anti-CD38 therapy and the development of biomarkers and new backbone regimens with CD38 antibodies will be important steps in building more personalized treatment for patients with MM.
Collapse
Affiliation(s)
- Thomas G. Martin
- Hematology/Oncology, University of California San Francisco, San Francisco, CA 94143-0324, USA;
| | - Kathryn Corzo
- Sanofi Oncology, Cambridge, MA 02142, USA; (K.C.); (H.v.d.V.); (G.A.); (F.C.); (M.S.); (R.M.); (H.L.); (D.W.); (C.Z.)
| | - Marielle Chiron
- Translational and Experimental Medicine, Sanofi Research & Development, 94403 Vitry-sur-Seine, France;
| | - Helgi van de Velde
- Sanofi Oncology, Cambridge, MA 02142, USA; (K.C.); (H.v.d.V.); (G.A.); (F.C.); (M.S.); (R.M.); (H.L.); (D.W.); (C.Z.)
| | - Giovanni Abbadessa
- Sanofi Oncology, Cambridge, MA 02142, USA; (K.C.); (H.v.d.V.); (G.A.); (F.C.); (M.S.); (R.M.); (H.L.); (D.W.); (C.Z.)
| | - Frank Campana
- Sanofi Oncology, Cambridge, MA 02142, USA; (K.C.); (H.v.d.V.); (G.A.); (F.C.); (M.S.); (R.M.); (H.L.); (D.W.); (C.Z.)
| | - Malini Solanki
- Sanofi Oncology, Cambridge, MA 02142, USA; (K.C.); (H.v.d.V.); (G.A.); (F.C.); (M.S.); (R.M.); (H.L.); (D.W.); (C.Z.)
| | - Robin Meng
- Sanofi Oncology, Cambridge, MA 02142, USA; (K.C.); (H.v.d.V.); (G.A.); (F.C.); (M.S.); (R.M.); (H.L.); (D.W.); (C.Z.)
| | - Helen Lee
- Sanofi Oncology, Cambridge, MA 02142, USA; (K.C.); (H.v.d.V.); (G.A.); (F.C.); (M.S.); (R.M.); (H.L.); (D.W.); (C.Z.)
| | - Dmitri Wiederschain
- Sanofi Oncology, Cambridge, MA 02142, USA; (K.C.); (H.v.d.V.); (G.A.); (F.C.); (M.S.); (R.M.); (H.L.); (D.W.); (C.Z.)
| | - Chen Zhu
- Sanofi Oncology, Cambridge, MA 02142, USA; (K.C.); (H.v.d.V.); (G.A.); (F.C.); (M.S.); (R.M.); (H.L.); (D.W.); (C.Z.)
| | - Alexey Rak
- Integrated Drug Discovery, Sanofi Research & Development, 94403 Vitry-sur-Seine, France;
| | | |
Collapse
|
6
|
Batorov EV, Pronkina NV, Tikhonova MA, Kryuchkova IV, Sergeevicheva VV, Sizikova SA, Ushakova GY, Aristova TA, Batorova DS, Shishkova IV, Gilevich AV, Shevela EY, Ostanin AA, Chernykh ER. Increased circulating CD3 + T cells are associated with early relapse following autologous hematopoietic stem cell transplantation in patients with classical Hodgkin lymphoma. Leuk Lymphoma 2019; 60:2488-2497. [PMID: 31609150 DOI: 10.1080/10428194.2019.1581934] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Non-malignant host immune cells are the main substrate in classical Hodgkin lymphoma (HL) microenvironment. Reconstitution of lymphocyte populations following the high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (auto-HSCT) can support tumor growth in HL patients. We investigated recovery dynamics of circulating CD3+, CD4+, CD8+, CD16+/CD56+, CD19+, CD4+FOXP3+ lymphocytes following auto-HSCT in 79 HL patients and assessed relationship between these populations and the development of early relapse. Studied populations were not statistically significant between patients with high or standard/intermediate risk of relapse. CD3+ T cells at the time of engraftment were increased in patients with the early relapse of HL compared to non-relapsed patients (PU = 0.0028). Area under the curve was 0.76 (р = .0037). In logistic regression models, CD3+ T cell count was associated with early relapse/progression as a trend. These findings elucidate several interactions between early systemic T cell recovery and tumor progression following HDC with auto-HSCT.
Collapse
Affiliation(s)
- Egor V Batorov
- Laboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia
| | - Natalia V Pronkina
- Laboratory of Clinical Immunology, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia
| | - Marina A Tikhonova
- Laboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia
| | - Irina V Kryuchkova
- Department of Hematology and Bone Marrow Transplantation, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia
| | - Vera V Sergeevicheva
- Department of Hematology and Bone Marrow Transplantation, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia
| | - Svetlana A Sizikova
- Department of Hematology and Bone Marrow Transplantation, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia
| | - Galina Y Ushakova
- Department of Hematology and Bone Marrow Transplantation, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia
| | - Tatiana A Aristova
- Department of Hematology and Bone Marrow Transplantation, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia
| | - Dariya S Batorova
- Department of Hematology and Bone Marrow Transplantation, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia
| | - Irina V Shishkova
- Laboratory of Clinical Immunology, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia
| | - Andrey V Gilevich
- Intensive Care Unit, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia
| | - Ekaterina Y Shevela
- Laboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia
| | - Alexander A Ostanin
- Laboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia
| | - Elena R Chernykh
- Laboratory of Cellular Immunotherapy, Research Institute of Fundamental and Clinical Immunology , Novosibirsk , Russia
| |
Collapse
|
7
|
Henry M, Buck S, Savaşan S. Flow cytometry for assessment of the tumor microenvironment in pediatric Hodgkin lymphoma. Pediatr Blood Cancer 2018; 65:e27307. [PMID: 30009533 PMCID: PMC6854677 DOI: 10.1002/pbc.27307] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/27/2017] [Revised: 05/20/2018] [Accepted: 06/01/2018] [Indexed: 01/09/2023]
Abstract
BACKGROUND The role of flow cytometry in diagnosis and management of Hodgkin lymphoma (HL) remains limited. As knowledge emerges of the tumor microenvironment in this disease, various methods are being evaluated in its study. This study examines the microenvironment using flow cytometry to assess differences between subtypes and clinicopathologic correlates. PROCEDURE A retrospective cross-sectional study was performed analyzing the tumor immunophenotype, by flow cytometry, for 31 children with classical HL. Correlation was made with patient information, including outcome. RESULTS The makeup of the tumor microenvironment varies across subtype of HL, with T cells predominating in nodular sclerosis (NS), and similar proportions of B and T cells in mixed cellularity (MC). CD4 cells predominate in NS, whereas CD8 more so in MC subtype. The rate of continuous complete remission is significantly higher in the MC subgroup. Last, the proportion of HLA-DR/CD38 copositive lymphocytes was an independent prognostic factor for relapse/refractoriness. CONCLUSIONS This study indicates that flow cytometry can be used to examine the tumor microenvironment in HL and that percentage of HLA-DR/CD38 copositive lymphocytes may be a biomarker for relapse and refractoriness in pediatric HL.
Collapse
Affiliation(s)
- Meret Henry
- Division of Hematology/Oncology, Department of Pediatrics, Children’s Hospital of Michigan, Detroit, Michigan,Department of Pediatrics, Wayne State University, Detroit, Michigan
| | - Steven Buck
- Division of Hematology/Oncology, Department of Pediatrics, Children’s Hospital of Michigan, Detroit, Michigan
| | - Süreyya Savaşan
- Division of Hematology/Oncology, Department of Pediatrics, Children’s Hospital of Michigan, Detroit, Michigan,Department of Pediatrics, Wayne State University, Detroit, Michigan
| |
Collapse
|
8
|
Péricart S, Tosolini M, Gravelle P, Rossi C, Traverse-Glehen A, Amara N, Franchet C, Martin E, Bezombes C, Laurent G, Brousset P, Fournié JJ, Laurent C. Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining. Cancers (Basel) 2018; 10:cancers10110415. [PMID: 30384489 PMCID: PMC6266061 DOI: 10.3390/cancers10110415] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2018] [Revised: 10/23/2018] [Accepted: 10/27/2018] [Indexed: 02/06/2023] Open
Abstract
Therapeutic blockade of PD-1/PD-L1 shows promising results in Hodgkin's lymphoma (HL) and in some diffuse large B-cell lymphoma (DLBCL) patients, but biomarkers predicting such responses are still lacking. To this end, we recently developed a transcriptional scoring of immune escape (IE) in cancer biopsies. Using this method in DLBCL, we identified four stages of IE correlated with overall survival, but whether Hodgkin's lymphomas (HL) also display this partition was unknown. Thus, we explored the transcriptomic profiles of ~1000 HL and DLBCL using a comparative meta-analysis of their bulk microarrays. Relative to DLBCL, the HL co-clustered at the advanced stage of immune escape, displaying significant enrichment of both IE and T-cell activation genes. Analyses via transcriptome deconvolution and immunohistochemistry showed more CD3⁺ and CD4⁺ tumor-infiltrating lymphocytes (TILs) in HL than DLBCL. Both HL and non-GCB DLBCL shared a high abundance of infiltrating CD8⁺ T-cells, but HL had less CD68⁺CD163⁺ macrophages. The same cellular distribution of PD-1 and TIM-3 was observed in HL and DLBCL, though HL had more PD-L1 tumor cells and LAG-3 ME cells. This study illuminates the advanced stage of immune activation and escape in HL, consistent with the response to checkpoint blockade therapies for this type of lymphoma.
Collapse
Affiliation(s)
- Sarah Péricart
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France.
- Université Toulouse III Paul-Sabatier, 31330 Toulouse, France.
- Centre de Recherches en Cancérologie de Toulouse, ERL 5294 CNRS, 31100 Toulouse, France.
- Laboratoire d'Excellence 'TOUCAN', 31059 Toulouse, France.
- Programme Hospitalo-Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France.
- Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.
- Departement de Pathologie, CHU Toulouse, Institut Universitaire du Cancer-Oncopole de Toulouse, 31059 CEDEX 09 Toulouse, France.
| | - Marie Tosolini
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France.
- Université Toulouse III Paul-Sabatier, 31330 Toulouse, France.
- Centre de Recherches en Cancérologie de Toulouse, ERL 5294 CNRS, 31100 Toulouse, France.
- Laboratoire d'Excellence 'TOUCAN', 31059 Toulouse, France.
- Programme Hospitalo-Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France.
- Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.
- Departement de Pathologie, CHU Toulouse, Institut Universitaire du Cancer-Oncopole de Toulouse, 31059 CEDEX 09 Toulouse, France.
| | - Pauline Gravelle
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France.
- Université Toulouse III Paul-Sabatier, 31330 Toulouse, France.
- Centre de Recherches en Cancérologie de Toulouse, ERL 5294 CNRS, 31100 Toulouse, France.
- Laboratoire d'Excellence 'TOUCAN', 31059 Toulouse, France.
- Programme Hospitalo-Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France.
- Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.
- Departement de Pathologie, CHU Toulouse, Institut Universitaire du Cancer-Oncopole de Toulouse, 31059 CEDEX 09 Toulouse, France.
| | - Cédric Rossi
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France.
- Université Toulouse III Paul-Sabatier, 31330 Toulouse, France.
- Centre de Recherches en Cancérologie de Toulouse, ERL 5294 CNRS, 31100 Toulouse, France.
- Laboratoire d'Excellence 'TOUCAN', 31059 Toulouse, France.
- Programme Hospitalo-Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France.
- Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.
- Hématologie Clinique, CHU Dijon, 21000 Dijon, France.
| | | | - Nadia Amara
- Université Toulouse III Paul-Sabatier, 31330 Toulouse, France.
- Departement de Pathologie, CHU Toulouse, Institut Universitaire du Cancer-Oncopole de Toulouse, 31059 CEDEX 09 Toulouse, France.
| | - Camille Franchet
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France.
- Université Toulouse III Paul-Sabatier, 31330 Toulouse, France.
- Centre de Recherches en Cancérologie de Toulouse, ERL 5294 CNRS, 31100 Toulouse, France.
- Laboratoire d'Excellence 'TOUCAN', 31059 Toulouse, France.
- Programme Hospitalo-Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France.
- Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.
- Departement de Pathologie, CHU Toulouse, Institut Universitaire du Cancer-Oncopole de Toulouse, 31059 CEDEX 09 Toulouse, France.
| | - Elodie Martin
- Biostatistics Unit, Institut Claudius Regaud, IUCT-O, 31059 CEDEX 09 Toulouse, France.
| | - Christine Bezombes
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France.
- Université Toulouse III Paul-Sabatier, 31330 Toulouse, France.
- Centre de Recherches en Cancérologie de Toulouse, ERL 5294 CNRS, 31100 Toulouse, France.
- Laboratoire d'Excellence 'TOUCAN', 31059 Toulouse, France.
- Programme Hospitalo-Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France.
- Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.
| | - Guy Laurent
- Université Toulouse III Paul-Sabatier, 31330 Toulouse, France.
- Programme Hospitalo-Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France.
- Departement d'Hematologie, CHU Toulouse, Institut Universitaire du Cancer-Oncopole de Toulouse, 31059 CEDEX 09 Toulouse, France.
| | - Pierre Brousset
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France.
- Université Toulouse III Paul-Sabatier, 31330 Toulouse, France.
- Centre de Recherches en Cancérologie de Toulouse, ERL 5294 CNRS, 31100 Toulouse, France.
- Laboratoire d'Excellence 'TOUCAN', 31059 Toulouse, France.
- Programme Hospitalo-Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France.
- Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.
- Departement de Pathologie, CHU Toulouse, Institut Universitaire du Cancer-Oncopole de Toulouse, 31059 CEDEX 09 Toulouse, France.
| | - Jean-Jacques Fournié
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France.
- Université Toulouse III Paul-Sabatier, 31330 Toulouse, France.
- Centre de Recherches en Cancérologie de Toulouse, ERL 5294 CNRS, 31100 Toulouse, France.
- Laboratoire d'Excellence 'TOUCAN', 31059 Toulouse, France.
- Programme Hospitalo-Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France.
- Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.
| | - Camille Laurent
- Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, 31100 Toulouse, France.
- Université Toulouse III Paul-Sabatier, 31330 Toulouse, France.
- Centre de Recherches en Cancérologie de Toulouse, ERL 5294 CNRS, 31100 Toulouse, France.
- Laboratoire d'Excellence 'TOUCAN', 31059 Toulouse, France.
- Programme Hospitalo-Universitaire en Cancérologie CAPTOR, 31059 Toulouse, France.
- Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.
- Departement de Pathologie, CHU Toulouse, Institut Universitaire du Cancer-Oncopole de Toulouse, 31059 CEDEX 09 Toulouse, France.
| |
Collapse
|
9
|
Wein F, Weniger MA, Höing B, Arnolds J, Hüttmann A, Hansmann ML, Hartmann S, Küppers R. Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma. Cancer Immunol Res 2017; 5:1122-1132. [PMID: 29070649 DOI: 10.1158/2326-6066.cir-17-0325] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Revised: 08/15/2017] [Accepted: 10/13/2017] [Indexed: 11/16/2022]
Abstract
The cellular microenvironment in classical Hodgkin lymphoma (cHL) is dominated by a mixed infiltrate of inflammatory cells with typically only about 1% Hodgkin and Reed/Sternberg (HRS) tumor cells. T cells are usually the largest population of cells in the cHL microenvironment, encompassing T helper (Th) cells, regulatory T cells (Tregs), and cytotoxic T cells. Th cells and Tregs presumably provide essential survival signals for HRS cells. Tregs are also involved in rescuing HRS cells from antitumor immune responses. An understanding of the immune evasion strategies of HRS cells is not only relevant for a characterization of the pathophysiology of cHL but is also clinically relevant, given the current treatment approaches targeting checkpoint inhibitors. Here, we characterized the cHL-specific CD4+ T-cell infiltrate regarding its role in immune evasion. Global gene expression analysis of CD4+ Th cells and Tregs isolated from cHL lymph nodes and reactive tonsils revealed that Treg signatures were enriched in CD4+ Th cells of cHL. Hence, HRS cells may induce Treg differentiation in Th cells, a conclusion supported by in vitro studies with Th cells and cHL cell lines. We also found evidence for immune-suppressive purinergic signaling and a role of the inhibitory receptor-ligand pairs B- and T-cell lymphocyte attenuator-herpesvirus entry mediator and CD200R-CD200 in promoting immune evasion. Taken together, this study highlights the relevance of Treg induction and reveals new immune checkpoint-driven immune evasion strategies in cHL. Cancer Immunol Res; 5(12); 1122-32. ©2017 AACR.
Collapse
Affiliation(s)
- Frederik Wein
- Institute of Cell Biology (Cancer Research), Medical Faculty, University of Duisburg-Essen, Essen, Germany
| | - Marc A Weniger
- Institute of Cell Biology (Cancer Research), Medical Faculty, University of Duisburg-Essen, Essen, Germany
| | - Benedikt Höing
- Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
| | - Judith Arnolds
- Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
| | - Andreas Hüttmann
- Department of Hematology, University Hospital Essen, Essen, Germany
| | - Martin-Leo Hansmann
- Dr. Senckenberg Institute of Pathology, Goethe-University of Frankfurt/Main, Medical School, Frankfurt/Main, Germany
| | - Sylvia Hartmann
- Dr. Senckenberg Institute of Pathology, Goethe-University of Frankfurt/Main, Medical School, Frankfurt/Main, Germany
| | - Ralf Küppers
- Institute of Cell Biology (Cancer Research), Medical Faculty, University of Duisburg-Essen, Essen, Germany.
| |
Collapse
|
10
|
Alonso-Álvarez S, Vidriales MB, Caballero MD, Blanco O, Puig N, Martin A, Peñarrubia MJ, Zato E, Galende J, Bárez A, Alcoceba M, Orfão A, González M, García-Sanz R. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. Leuk Lymphoma 2016; 58:1144-1152. [DOI: 10.1080/10428194.2016.1239263] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Sara Alonso-Álvarez
- IBMCC (USAL-CSIC), Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
| | | | | | - Oscar Blanco
- IBMCC (USAL-CSIC), Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
| | - Noemí Puig
- IBMCC (USAL-CSIC), Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
| | - Alejandro Martin
- IBMCC (USAL-CSIC), Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
| | | | - Esther Zato
- Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | | | | | - Miguel Alcoceba
- IBMCC (USAL-CSIC), Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
| | - Alberto Orfão
- IBMCC (USAL-CSIC), Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
| | - Marcos González
- IBMCC (USAL-CSIC), Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
| | - Ramón García-Sanz
- IBMCC (USAL-CSIC), Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
| |
Collapse
|
11
|
Wein F, Küppers R. The role of T cells in the microenvironment of Hodgkin lymphoma. J Leukoc Biol 2015; 99:45-50. [PMID: 26320264 DOI: 10.1189/jlb.3mr0315-136r] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2015] [Accepted: 05/15/2015] [Indexed: 12/23/2022] Open
Abstract
The cellular microenvironment in HL is dominated by a mixed infiltrate of inflammatory cells with typically only 1 or a few percent of HRS tumor cells. HRS cells orchestrate this infiltrate by the secretion of a multitude of chemokines. T cells are usually the largest population of cells in the HL tissue, encompassing Th cells, T(regs), and CTLs. Th cells and T(regs) presumably provide essential survival signals for the HRS cells, and the T(regs) also play an important role in rescuing HRS cells from an attack by CTLs and NK cells. The interference with this complex interplay of HRS cells with other immune cells in the microenvironment may provide novel strategies for targeted immunotherapies.
Collapse
Affiliation(s)
- Frederik Wein
- Institute of Cell Biology (Cancer Research), Medical Faculty, University of Duisburg-Essen, Essen, Germany
| | - Ralf Küppers
- Institute of Cell Biology (Cancer Research), Medical Faculty, University of Duisburg-Essen, Essen, Germany
| |
Collapse
|
12
|
Wu D, Thomas A, Fromm JR. Reactive T cells by flow cytometry distinguish Hodgkin lymphomas from T cell/histiocyte-rich large B cell lymphoma. CYTOMETRY PART B-CLINICAL CYTOMETRY 2015; 90:424-32. [DOI: 10.1002/cyto.b.21261] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/21/2015] [Revised: 05/21/2015] [Accepted: 06/02/2015] [Indexed: 11/07/2022]
Affiliation(s)
- David Wu
- Department of Laboratory Medicine; University of Washington; Seattle Washington 98109
| | - Anju Thomas
- Department of Laboratory Medicine; University of Washington; Seattle Washington 98109
| | - Jonathan R. Fromm
- Department of Laboratory Medicine; University of Washington; Seattle Washington 98109
| |
Collapse
|